It’s been over two years of a pandemic with all its painful limitations and discussions between science and conspiracy scenarios. Now, almost everyone really knows the biotechnology company BioNTech (BNTX).
BioNTech announcement in mid-2020 that it would get the first vaccine against the SARS-CoV-2 coronavirus into regulatory approval that same year. The young German company provided many people with their first light at the end of the Corona tunnel.
Overwhelming First Quarter of 2022 for BioNTech
BioNTech brought in sales of just under €6.4 billion in the first quarter of the current year. In the corresponding period of the previous year, they were at €2.05 billion.
They’ve had similar success this year. In the first quarter, their sales rose from €1.12 billion (2021) up to €6.37 billion (2022). These increases strongly exceeded the expectations of most analysts.
Things Will Not Go On As Strongly As This
However, it’s also clear that BioNTech is still benefiting from the high orders from the previous year. For the full year, analysts expect profits to fall to between €13 billion and €17 billion.
The bottom line is that almost 60% of the world’s population is considered vaccinated. Now, we see many vaccination centers are virtually deserted. And many vaccine manufacturers are complaining of impending overcapacity.
Nevertheless, the analysts’ assessments of BioNTech speak a clear language: the average analyst recommendation is to “stock up”. After all, 10 out of 16 analysts recommend holding the company’s shares. Similarly, not a single one advises reducing or even selling. The average analyst price target is €224.60, which represents a return opportunity of over +60%.